MedTrace Logo

Gandouling in the Treatment of Wilson's Disease

NCT05305872 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2024-02-09

No results posted yet for this study

Summary

To evaluate the efficacy and safety of gandouling tablet in the treatment of clinical symptoms of Wilson's diasease.

Conditions

  • Wilson's Disease

Interventions

DRUG

Gandouling

The experimental group was given gandouling tablet + zinc gluconate simulant; The course of treatment was 24 weeks.

Sponsors & Collaborators

  • Jun Li

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-01
Primary Completion
2023-03-01
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05305872 on ClinicalTrials.gov